BRU : ARGX.BR

argenx SE

$784.79999 EUR

$26.4 (3.48%)

Volume
12.01K
Average Volume
92.64K
Market Capitalization
$48.8B
P/E Ratio
50.17
Dividend Yield
0.00%
Price Target
Year High
$833.60
Year Low
$483.10
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$5.23
Company Overview

BRU

Karen Massey

Biotechnology

Healthcare

ARGX.BR

1863

NL

EUR

https://www.argenx.com

31 10 703 8441

N0610Q109

N/A

Liquidity Metrics

0.01

5.23

4.87

2.64

0.00

Sales & Valuation

$4.15B

16.49

7.51

74.98

12.09

Profitability

$20.37

$1.34B

33.42%

32.03%

16.82%

13.00%

P/E Metrics

50.17

0.07

0.07

Analyst Price Target & Rating

Neutral

3/5

29 Analysts

%

Financial Health Scores

22.47

5/9

$5.58B

$8.68B

$1.36B

$1.08B

Key Metrics (TTM)

No key metrics data available.

Company Executives
Name Title
Karl Gubitz Chief Financial Officer
Hans de Haard Ir Co-Founder & Member of Board Advisors
Timothy Van Hauwermeiren EMBA Co-Founder & Non-Independent Non-Executive Chairman of the Board
Marc Schorpion Global Head of Human Resources
Karen Massey Chief Executive Officer & Executive Director
Malini Moorthy General Counsel & Corporate Secretary
Peter Ulrichts Chief Scientific Officer
Arjen Lemmen Vice President of Corporate Development & Strategy
Filip Borgions Chief Technology Innovation Officer
Andria Wilk Global Head of Quality
Luc Truyen Chief Medical Officer
Poll Results

No votes yet today — be the first to share your view!

About argenx SE (BRU:ARGX.BR) Stock

argenx SE is a biotechnology enterprise dedicated to developing a diverse array of therapeutic agents for autoimmune conditions. Its operational reach extends across the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, and France. The company's primary drug candidate, efgartigimod, is currently in advanced stages of clinical investigation. It is being evaluated in Phase III trials for several indications, including myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy. Furthermore, efgartigimod is progressing through Phase II/III clinical trials for bullous pemphigoid and idiopathic inflammatory myopathy, with its subcutaneous ENHANZE formulation also undergoing preclinical assessment. Beyond its lead prod ... uct, argenx SE maintains an active pipeline of immunology-focused programs. This includes cusatuzumab, targeted at hematological cancers and high-risk myelodysplastic syndromes (MDS); ARGX-119, an antibody designed to inhibit muscle-specific tyrosine kinase; ARGX-117, slated for severe autoimmune disorders; ARGX-118, aimed at mitigating airway inflammation; and ARGX-120, another candidate for the treatment of autoimmune diseases. The firm also engages in collaborations for additional investigational products, such as ARGX-115 for cancer therapy, ARGX-112 which targets the interleukin-22 receptor, and ARGX-114, an antibody engineered to block the MET receptor. argenx SE has forged strategic alliances with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S. It also holds numerous collaboration and licensing agreements with partners including Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., the University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. Established in 2008, argenx SE is headquartered in Breda, the Netherlands.

Frequently Asked Questions

What is the current argenx SE (ARGX.BR) stock price?

argenx SE(BRU:ARGX.BR) stock price is $784.79999 in the last trading session. During the trading session, ARGX.BR stock reached the peak price of $833.6 while $483.1 was the lowest point it dropped to. The percentage change in ARGX.BR stock occurred in the recent session was 3.48% while the dollar amount for the price change in ARGX.BR stock was $26.4.

ARGX.BR's industry and sector of operation?

The BRU listed ARGX.BR is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of ARGX.BR?

Karl Gubitz | Chief Financial Officer
Hans de Haard Ir | Co-Founder & Member of Board Advisors
Timothy Van Hauwermeiren EMBA | Co-Founder & Non-Independent Non-Executive Chairman of the Board
Marc Schorpion | Global Head of Human Resources
Karen Massey | Chief Executive Officer & Executive Director

How many employees does ARGX.BR have?

Number of ARGX.BR employees currently stands at 1863. ARGX.BR operates from Laarderhoogtweg 25, Amsterdam, NH 1101 EB, NL.

Link for ARGX.BR official website?

Official Website of ARGX.BR is: https://www.argenx.com

How do I contact ARGX.BR?

ARGX.BR could be contacted at phone #31 10 703 8441 and can also be accessed through its website. ARGX.BR operates from Laarderhoogtweg 25, Amsterdam, NH 1101 EB, NL.

How many shares of ARGX.BR are traded daily?

The average number of ARGX.BR shares traded daily for last 3 months was 92.64K.

What is the market cap of ARGX.BR currently?

The market value of ARGX.BR currently stands at $48.8B with its latest stock price at $784.79999